1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Neuroendocrine Carcinoma – Pipeline Review, H1 2013

Neuroendocrine Carcinoma – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 25 pages

Neuroendocrine Carcinoma – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Neuroendocrine Carcinoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Neuroendocrine Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuroendocrine Carcinoma. Neuroendocrine Carcinoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Neuroendocrine Carcinoma.
- A review of the Neuroendocrine Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Neuroendocrine Carcinoma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Neuroendocrine Carcinoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Neuroendocrine Carcinoma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Neuroendocrine Carcinoma - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Neuroendocrine Carcinoma Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Neuroendocrine Carcinoma 6
Neuroendocrine Carcinoma Therapeutics under Development by Companies 8
Early Clinical Stage Products 9
Comparative Analysis 9
Neuroendocrine Carcinoma Therapeutics - Products under Development by Companies 10
Companies Involved in Neuroendocrine Carcinoma Therapeutics Development 11
Novartis AG 11
Neuroendocrine Carcinoma - Therapeutics Assessment 12
Assessment by Monotherapy Products 12
Assessment by Route of Administration 13
Assessment by Molecule Type 15
Drug Profiles 17
pasireotide - Drug Profile 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Neuroendocrine Carcinoma Therapeutics - Drug Profile Updates 20
Neuroendocrine Carcinoma Therapeutics - Dormant Products 23
Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 24
Contact Us 25
Disclaimer 25



List of Tables

Number of Products Under Development for Neuroendocrine Carcinoma, H1 2013 6
Products under Development for Neuroendocrine Carcinoma - Comparative Analysis, H1 2013 7
Number of Products under Development by Companies, H1 2013 8
Comparative Analysis by Early Clinical Stage Development, H1 2013 9
Products under Development by Companies, H1 2013 10
Novartis AG, H1 2013 11
Assessment by Monotherapy Products, H1 2013 12
Assessment by Stage and Route of Administration, H1 2013 14
Assessment by Stage and Molecule Type, H1 2013 16
Neuroendocrine Carcinoma Therapeutics - Drug Profile Updates 20
Neuroendocrine Carcinoma Therapeutics - Dormant Products 23



List of Figures

Number of Products under Development for Neuroendocrine Carcinoma, H1 2013 6
Products under Development for Neuroendocrine Carcinoma - Comparative Analysis, H1 2013 7
Products under Development by Companies, H1 2013 8
Early Clinical Stage Products, H1 2013 9
Assessment by Monotherapy Products, H1 2013 12
Assessment by Route of Administration, H1 2013 13
Assessment by Stage and Route of Administration, H1 2013 14
Assessment by Molecule Type, H1 2013 15
Assessment by Stage and Molecule Type, H1 2013 16

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

  • $ 6400
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $9,800.  DataPack (test volumes, sales forecasts, supplier shares) $6,400. Highlights Comprehensive 620-page analysis of the US tumor marker testing market.Major issues pertaining to the ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in Australia - Forecast

  • February 2017
    4 pages
  • Cancer  

    Ovarian Cancer  

  • Australia  

    Oceania  

View report >

Cancer Statistics in the UK

  • February 2017
    11 pages
  • Cancer  

  • United Kingdom  

    Australia  

    Denmark  

View report >

Cancer Statistics in the UK

  • February 2017
    18 pages
  • Cancer  

  • United Kingdom  

View report >

Cancer Statistics

8 days ago

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.